Legend Biotech (LEGN) Receivables (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Receivables data on file, last reported at $13.1 million in Q4 2025.

• In Q4 2025, Receivables rose 82.45% year-over-year to $13.1 million; the TTM figure through Dec 2025 stood at $13.1 million (up 82.45% YoY), while the FY2025 annual figure was $13.1 million, up 82.45% from the prior year.
• Receivables improved to $13.1 million in Q4 2025, from $1.2 million in the prior quarter.
• Across five years, Receivables topped out at $100.8 million in Q4 2023 and bottomed at $1967.0 in Q1 2021.
• A 5-year average of $16.0 million and a median of $2.4 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 2599747.48% — and 2023, when it tumbled 99.89%.
• Year by year, Receivables stood at $51.2 million in 2021, then sank by 97.97% to $1.0 million in 2022, then surged by 9613.97% to $100.8 million in 2023, then sank by 92.88% to $7.2 million in 2024, then surged by 82.45% to $13.1 million in 2025.
• The last three Receivables figures came in at $13.1 million (Q4 2025), $1.2 million (Q3 2025), and $27.6 million (Q2 2025), per Business Quant data.

Peer Comparison